Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Pull Lung Cancer Med Exkivity in US after Trial Miss
October 4, 2023
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
- Tarlige Tops July Rep Promotion Ranking, Takes Back Crown from Mounjaro for GPs: Intage
October 3, 2023
- Kyorin to Cut Non-Sales Jobs through Voluntary Buyout
October 3, 2023
- FDA Gives Thumbs-Down for MEDRx/DWTI’s Lidocaine Patch
October 3, 2023
- Nihon Servier Launches Blood Cancer Med Oncaspar in Japan
October 3, 2023
- Chugai’s NMOSD Drug Enspryng Now Available in Taiwan
October 3, 2023
- Izumi Yoshida Named Japan President of CSL Behring
October 2, 2023
- GSK, Kyushu University Forge Oncology Partnership
October 2, 2023
- Takeda Seeks Japan Nod for Hutchmed’s Colorectal Cancer Drug
October 2, 2023
- Pfizer Japan Files New Dosage Forms for XBB.1.5 COVID Vaccine
October 2, 2023
- Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
September 29, 2023
- Eisai/Tokio Marine Launch Dementia Insurance Ahead of Leqembi Rollout
September 29, 2023
- Acoalan Misses Mark in PIII Preeclampsia Trial: Kyowa Kirin
September 29, 2023
- Pioneer Director Atsushi Kitamura Picked as Astellas CFO
September 29, 2023
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- Shionogi’s Fragile X Syndrome Drug Gets Rare Pediatric Disease Tag in US
September 29, 2023
- Lilly Japan to Build New Manufacturing Facility, Eyes Mounjaro Supply Boost
September 28, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…